Parallax Volatility Advisers, L.P. Neurocrine Biosciences Inc Call Options Transaction History

Parallax Volatility Advisers, L.P.

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $2.82 Million - $3.51 Million	30,000 New	30,000 $3.38 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $2.2 Million - $2.53 Million	25,500 New	25,500 $2.45 Million
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $7.55 Million - $10.3 Million	-86,200 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$87.57 - $119.4 $7.5 Million - $10.2 Million	85,600 Added 14266.67%	86,200 $8.38 Million
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $52,146 - $64,998	600 New	600 $58,000
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $2.67 Million - $3.33 Million	-30,700 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $1.72 Million - $2.42 Million	17,900 Added 139.84%	30,700 $2.95 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $1.09 Million - $1.67 Million	12,800 New	12,800 $1.56 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $4.34 Million - $5.93 Million	-50,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $3.2 Million - $4.22 Million	-46,100 Reduced 47.97%	50,000 $4.41 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $4.86 Million - $8.84 Million	71,100 Added 284.4%	96,100 $6.86 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $2.47 Million - $3.15 Million	25,000 New	25,000 $3.07 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $3.77 Million - $5.3 Million	-50,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $3.79 Million - $4.62 Million	50,000 New	50,000 $4.15 Million

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.